Clinical Trial Update: Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating pembrolizumab with chemoradiotherapy followed by surgery for esophageal squamous cell carcinoma; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Esophageal Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN